相关实验视频

Updated: Jun 13, 2025

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

确定SNHG11作为肺高血压治疗的治疗点

Huayang Li¹, Quan Liu¹, Chiyu Liu²

¹Department of Cardiac Surgery, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.

American journal of respiratory cell and molecular biology

|September 12, 2024

概括

研究人员发现,在肺高血压 (PH) 中,长非编码RNA SNHG11 的下调. 恢复SNHG11水平可能通过针对血管重塑为PH提供一种新的治疗策略.

科学领域:

分子生物学分子生物学
心血管研究研究心血管研究
基因组学就是基因组学.

背景情况:

肺高血压 (PH) 涉及血管重塑和内皮功能障碍,目前的治疗方法往往不足.
长非编码RNAs (lncRNAs) 是细胞过程的关键调节者,但在PH中没有得到充分的研究.
现有的PH疗法主要针对血管活性失衡,而不是潜在的血管改造.

研究的目的:

为了研究 lncRNAs 在肺高血压病变中的作用.
使用转录基因数据识别涉及PH的特定lncRNA.
探索PH中确定的lncRNAs的功能和机制意义.

主要方法:

对GSE113439人类肺组织数据集的权重基因同表达网络分析 (WGCNA).
在实验室使用人类肺动脉内皮细胞 (HPAECs) 的功能测试.
在体内研究涉及PH的低氧大鼠模型.

主要成果:

在PH样本中,IncRNA SNHG11始终被发现是下调的.
在HPAEC中SNHG11的淘汰影响了炎症,增殖,亡以及JAK/STAT和MAPK信号通路.
证实SNHG11能稳定结合体组件PRPF8,影响细胞功能.
在大鼠模型中,SNHG11的敲除减弱了PH发育,改善了右心室功能.

结论:

SNHG11是肺高血压病变的关键调节剂.
SNHG11影响了PH中涉及的关键细胞过程,包括炎症和血管重塑.
SNHG11代表了肺高血压的潜在新型治疗点.

关键词:

在SNHG11中,SNHG11是SNHG11中的一个.长非编码RNA是什么意思肺动脉内皮细胞肺动脉内皮细胞肺高血压是一种肺高血压.权重基因同表达网络分析

更多相关视频

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension

Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension

Published on: February 11, 2017

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...